Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequential Therapy Clear all
Completed Phase 1Phase 2 Interventional Results available

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

NCT04630756
View directory record Official record
Conditions
Advanced Haematological Malignancies
Interventions
AZD4573, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04267848
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1150
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02121990
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Paclitaxel,, Bevacizumab, Cisplatin, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

NCT01027364
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
Factor IX (rFIXFc), rFIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 3 Interventional

Sequential Compression Devices for Treatment of Restless Legs Syndrome

NCT00479531
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
AirCast Sequential Compression Device
Device
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Sleep Disorders Center, Walter Reed Army Medical Center, District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2007 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT04243083
View directory record Official record
Conditions
Healthy
Interventions
TLL018 tablet, placebo
Drug
Lead sponsor
TLL Pharmaceutical, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

NCT05758246
View directory record Official record
Conditions
Sepsis, Acute Infection, Organ Failure
Interventions
Fisetin-dose 1, Fisetin-dose 2, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Gainesville, Florida • Iowa City, Iowa • Burnsville, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Not listed Phase 2 Interventional

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01730716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Human spinal cord stem cell implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406
View directory record Official record
Conditions
Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases
Interventions
DNX-2401, pembrolizumab
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers

NCT01136928
View directory record Official record
Conditions
Healthy Volunteers
Interventions
American ginseng
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

NCT01199367
View directory record Official record
Conditions
Breast Cancer
Interventions
KW-2450 in combination with lapatinib and letrozole
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Long Beach, California • Los Angeles, California • Deerfield Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

NCT00921336
View directory record Official record
Conditions
Solid Tumor
Interventions
KW-2450
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Not applicable Interventional

AROMA-NT: Essential Oils and Wearable TENS Device for Chronic Nausea

NCT07720336
View directory record Official record
Conditions
Chronic Nausea, Anxiety
Interventions
Inhaled Essential Oils, Wearable TENS Device
Other · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

NCT06439693
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions
Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Not applicable Interventional

Superior Parietal iTBS for PD-MCI

NCT07701785
View directory record Official record
Conditions
Parkinson Disease, Mild Cognitive Impairment
Interventions
Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Not applicable Interventional

Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial

NCT06976307
View directory record Official record
Conditions
Disabilities, Obesity and Overweight, Prediabetes
Interventions
High Carbohydrate Diet, Reduced Carbohydrate Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

NCT01057121
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Not applicable Interventional

Cranial Electrotherapy Stimulation and Brain Imaging for Gulf War Syndrome

NCT07151248
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Cranial electrical/electrotherapy stimulation (CES), Sham Cranial electrical/electrotherapy stimulation (CES)
Device
Lead sponsor
Emory University
Other
Eligibility
40 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

NCT03446417
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ZN-e4
Drug
Lead sponsor
Zeno Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Duarte, California • Detroit, Michigan • East Setauket, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

NCT06854614
View directory record Official record
Conditions
Obesity
Interventions
Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®)
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 3:17 PM EDT